Pfizer PFE Other Noncash Income (Expense)
Other Noncash Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Pfizer in its filing.
Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.
The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pfizer's other noncash income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pfizer's other noncash income (expense)?
- Pfizer (PFE) reported other noncash income (expense) of $93M in Q1 2026.
- How has Pfizer's other noncash income (expense) changed year-over-year?
- Pfizer's other noncash income (expense) increased by 332.5% year-over-year, from -$40M to $93M.
- What is the long-term trend for Pfizer's other noncash income (expense)?
- Over 2 years (2023 to 2025), Pfizer's other noncash income (expense) has grown at a -63.3% compound annual growth rate (CAGR), from $3.49B to $470M.
- What does other noncash income (expense) mean?
- This captures miscellaneous non-cash adjustments to net income that do not fit into standard categories like depreciation or stock-based compensation. It includes items such as changes in fair value of certain liabilities or non-cash impairment charges.